Literature DB >> 29880579

Ischaemic cardiomyopathy and embolic stroke in a young adult with suspected synthetic cannabinoid use.

Sumera Khan1, Ahmad Hanif2, Michael F Wilson3,4.   

Abstract

The incidence of cardiovascular disease is increasing in young adults. We are reporting a case of acute stroke in a young patient with severe ischaemic cardiomyopathy in the absence of traditional risk factors. After ruling out atherosclerotic disease, his presentation was attributed to synthetic cannabinoid use. We then discussed the typical barriers in early diagnosis and limitations of laboratory testing in this condition. Due to the increase in abuse of these synthetic drugs among young adults, there is a need for high clinical suspicion which can help with early recognition and improve morbidity and mortality associated with these chemicals. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  drug misuse (including Addiction); ischaemic heart disease; stroke

Mesh:

Substances:

Year:  2018        PMID: 29880579      PMCID: PMC6040562          DOI: 10.1136/bcr-2018-224755

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  17 in total

Review 1.  Elevated factor VIII levels and the risk of thrombosis.

Authors:  P W Kamphuisen; J C Eikenboom; R M Bertina
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-05       Impact factor: 8.311

2.  Cannabis use, ischemic stroke, and multifocal intracranial vasoconstriction: a prospective study in 48 consecutive young patients.

Authors:  Valérie Wolff; Valérie Lauer; Olivier Rouyer; François Sellal; Nicolas Meyer; Jean Sébastien Raul; Cécile Sabourdy; Fazel Boujan; Christine Jahn; Rémy Beaujeux; Christian Marescaux
Journal:  Stroke       Date:  2011-04-21       Impact factor: 7.914

Review 3.  The behavioral profile of spice and synthetic cannabinoids in humans.

Authors:  Helge H Müller; Johannes Kornhuber; Wolfgang Sperling
Journal:  Brain Res Bull       Date:  2015-11-06       Impact factor: 4.077

4.  Recent declines in hospitalizations for acute myocardial infarction for Medicare fee-for-service beneficiaries: progress and continuing challenges.

Authors:  Jersey Chen; Sharon-Lise T Normand; Yun Wang; Elizabeth E Drye; Geoffrey C Schreiner; Harlan M Krumholz
Journal:  Circulation       Date:  2010-03-08       Impact factor: 29.690

5.  Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings.

Authors:  Maren Hermanns-Clausen; Stefan Kneisel; Bela Szabo; Volker Auwärter
Journal:  Addiction       Date:  2012-11-01       Impact factor: 6.526

6.  Recreational marijuana use and acute ischemic stroke: A population-based analysis of hospitalized patients in the United States.

Authors:  Kavelin Rumalla; Adithi Y Reddy; Manoj K Mittal
Journal:  J Neurol Sci       Date:  2016-02-04       Impact factor: 3.181

7.  Is thromboangiitis obliterans presentation influenced by cannabis addiction?

Authors:  Guillaume Martin-Blondel; Fabien Koskas; Patrice Cacoub; Damien Sène
Journal:  Ann Vasc Surg       Date:  2011-05       Impact factor: 1.466

8.  AKI associated with synthetic cannabinoids: a case series.

Authors:  Gautam Kantilal Bhanushali; Gaurav Jain; Huma Fatima; Leah J Leisch; Denyse Thornley-Brown
Journal:  Clin J Am Soc Nephrol       Date:  2012-12-14       Impact factor: 8.237

9.  Epidemiology and clinical features of toxicity following recreational use of synthetic cannabinoid receptor agonists: a report from the United Kingdom National Poisons Information Service.

Authors:  Jennifer Waugh; Javad Najafi; Leonard Hawkins; Simon L Hill; Michael Eddleston; J Allister Vale; John P Thompson; Simon H L Thomas
Journal:  Clin Toxicol (Phila)       Date:  2016-04-19       Impact factor: 4.467

10.  A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010.

Authors:  Christopher O Hoyte; Jeena Jacob; Andrew A Monte; Mohammed Al-Jumaan; Alvin C Bronstein; Kennon J Heard
Journal:  Ann Emerg Med       Date:  2012-05-09       Impact factor: 5.721

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.